Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies

NCT05537766 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

19

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision to terminate study.

Conditions

Relapsed/Refractory Waldenstrom Macroglobulinemia
Relapsed/Refractory Richter Transformation
Relapsed/Refractory Burkitt Lymphoma
Relapsed/Refractory Hairy Cell Leukemia

Interventions

BIOLOGICAL: Brexucabtagene Autoleucel
DRUG: Cyclophosphamide
DRUG: Fludarabine

Sponsor

Kite, A Gilead Company